Gosuranemab (BIIB092) is an N-terminal targeting tau-targeting antibody that displayed strong target engagement in the CSF of progressive supranuclear palsy (PSP) and AD patients, however it was subsequently discontinued due to a lack of efficacy (Boxer et al., 2019) (Shulman et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.